Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Follicular 17Lymphoma, B-Cell, Marginal Zone 17Leukemia, Myeloid, Acute 17Congenital Abnormalities 17Breast Neoplasms 16Lymphoma, Mantle-Cell 15Leukemia 15Lymphoma, Non-Hodgkin 14Lymphoma, Large B-Cell, Diffuse 14Multiple Myeloma 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma 11Burkitt Lymphoma 11Blast Crisis 11Myeloproliferative Disorders 10Myelodysplastic Syndromes 10Lymphoma, T-Cell, Cutaneous 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myeloid, Accelerated Phase 10Sezary Syndrome 9Mycosis Fungoides 9Leukemia, Myeloid, Chronic-Phase 9Waldenstrom Macroglobulinemia 8Lymphoma, Large-Cell, Anaplastic 8Hodgkin Disease 8Primary Myelofibrosis 7Pdgfra-Associated Chronic Eosinophilic Leukemia 6Neoplasms, Plasma Cell 6

Interventions

Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 6Tacrolimus 5Mycophenolic Acid 5Epoetin Alfa 5Colposcopy 5Celecoxib 5Busulfan 5Aminolevulinic Acid 5Sulindac 4Selenium 4Methotrexate 4Melphalan 4Cyclosporine 4Cetuximab 4Antilymphocyte Serum 4Polymerase Chain Reaction 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Gene Expression Profiling 3Etoposide 3Eflornithine 3Darbepoetin alfa 3Carboplatin 3Aspirin 3fludarabine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precancerous Conditions × Flow Cytometry × Clear all
NCT00629577 2017-02-01

SAGE

British Columbia Cancer Agency

Phase 1 Terminated
50 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡